Extended Data Fig. 8: Overall survival outcomes for patients with tumors that are TMB-low, PD-L1-null, or harboring mutations in the Wnt pathway.
(a) Kaplan–Meier curve of probability of OS in PD-L1 null patients (n = 41 patients) treated in the control arm (n = 23 patients) and SBRT arm (n = 18 patients). PD-L1 null patients have a trend of longer OS in the SBRT arm than in the control arm (median OS SBRT arm 7.21 months, control arm 6.05 months, log-rank P = 0.084). (b) Kaplan–Meier curve of probability of OS in TMB low patients (n = 43 patients) treated in the control arm (n = 21 patients) and SBRT arm (n = 22 patients). TMB low patients have numerically longer OS in the SBRT arm than patients in the control arm, though the difference is statistically insignificant (median OS SBRT arm 9.89 months, control arm 6.70 months, log-rank P = 0.16) (c) Kaplan–Meier curve of probability of OS in the SBRT arm in Wnt Mutated patients (n = 5 patients) and non-Wnt Mutated patients (n = 23 patients). Among patients in the SBRT arm, Wnt-mutated patients have longer OS than non-Wnt mutated patients (median OS Wnt mutated not reached, Wnt-wild type 9.92 months, log-rank P = 0.013). OS: overall survival.
